Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 141

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 141
---
) and increase the dilution to investors participating in this offering by approximately $0.10 per share, assuming that the assumed initial public offering price remains the same, and after deducting the underwriting discounts and commissions payable by us. If the underwriters exercise their option to purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be $12.11 per share, the increase in pro forma as adjusted net tangible book value per share to existing stockholders would be $0.23 per share, and the dilution per share to new investors would be $2.89 per share, in each case assuming the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions payable by us. The following table summarizes on a pro forma as adjusted basis as of June 30, 2025, the number of shares of common stock purchased or to be purchased from us, the total consideration paid or to be paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be paid by new investors in this offering. The calculation below is based on the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As the table below shows, investors participating in this offering will pay an average price per share substantially higher than our existing stockholders paid.

|                       |     | Shares Purchased 
 Number           |            |     | Percent |     |   |     | Total Consideration 
 Amount              |             |     | Percent |     |   |     | Weighted- 
 Average   
 Price Per 
 Share     |       |
|:----------------------|:----|:-----------------|-----------:|:----|:--------|----:|:--|:----|:--------------------|------------:|:----|:--------|----:|:--|:----|:----------|------:|
| Existing stockholders |     |                  |  3,433,470 |     |         |  17 | % |     | $                   | 124,886,172 |     |         |  33 | % |